GRAIL
Über GRAIL, INC
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Grail Inc at TD Cowen Healthcare Conference
03.03.2026
15:30
Konferenz-Präsentationen
Q1 2026 Grail Inc Earnings Release
11.05.2026
10:59
Veröffentlichungen von Geschäftszahlen
Grail Inc Annual Shareholders Meeting
29.05.2026
20:00
Jährliche Aktionärs-Meetings
Q2 2026 Grail Inc Earnings Release
10.08.2026
10:59
Veröffentlichungen von Geschäftszahlen